Report Overview

A spurring demand for cost-effective contract research, development, and manufacturing organizations’ (CRDMOs) services and solutions from global biopharmaceutical companies, a large skilled workforce, push for innovations, regulatory support, and supply chain diversification are expected to boost the growth of India CRDMO Market during the forecast period between 2025 and 2031.

India CRDMO Market – Industry Trends & Forecast Report, 2031

India CRDMO (contract research, development, and manufacturing organization) Market size was estimated at USD 22.61 billion in 2024. During the forecast period from 2025 to 2031, India CRDMO Market size is projected to grow at a CAGR of 13.10%, reaching a value of USD 53.53 billion by 2031. The rapid growth of India CRDMO Market is driven by a rising global demand for cost-effective drug development and manufacturing solutions. The country offers a skilled scientific workforce, robust infrastructure, and competitive pricing, attracting international pharmaceutical and biotech firms. Government initiatives supporting innovation and regulatory reforms enhance market appeal. Additionally, India’s strategic role in diversifying global supply chains and its growing capabilities in complex modalities like biologics and mRNA therapeutics further accelerate the growth of India CRDMO Market, positioning India as a preferred CRDMO destination worldwide.

CRDMO – Overview

A CRDMO (Contract Research, Development, and Manufacturing Organization) integrates drug discovery, development, and manufacturing services under one roof, streamlining pharmaceutical innovation. It enables biotech and pharma companies to accelerate timelines, reduce costs, and access specialized expertise across the value chain. CRDMOs support early-stage research, clinical trials, and commercial-scale production, offering flexibility and scalability. As demand for complex therapies grows, CRDMOs play a pivotal role in advancing global healthcare by bridging scientific innovation with efficient, compliant execution.

India CRDMO Market 

Growth Drivers

Rising Global Demand for Advanced Modalities

India CRDMO Market is witnessing robust growth, due to an increasing global demand for advanced therapeutic modalities, such as biologics, cell and gene therapies, and mRNA-based treatments. As biopharmaceutical innovation shifts toward complex molecules and precision medicine, India’s cost-effective infrastructure, skilled talent pool, and expanding capabilities in high-value biologics and specialty APIs position it as a preferred partner for global drug developers seeking scalable, quality-driven solutions across discovery, development, and manufacturing stages.

Challenges

Limited Funding and High Capital Costs

The growth in India CRDMO Market faces constraints, due to a limited access to venture capital and high upfront investment requirements for infrastructure, technology, and compliance. Smaller firms struggle to scale operations or adopt advanced modalities, slowing innovation and competitiveness. The capital-intensive nature of biologics and high-end manufacturing further widens the gap between global expectations and domestic capabilities, making it challenging for emerging players to compete with established international CDMOs in terms of quality, speed, and scalability.

Impact of Escalating Geopolitical Tensions on India CRDMO Market 

Intensifying geopolitical tensions among countries across the regions are reshaping global pharmaceutical supply chains, positioning India CRDMO Market as a strategic alternative to China-dependent models. Western firms increasingly seek risk-mitigated, diversified sourcing, driving demand for India’s cost-effective and compliant drug development services. However, volatility in trade policies, currency fluctuations, and export restrictions may disrupt operations and investor confidence. India’s ability to maintain neutrality, enhance regulatory alignment, and scale infrastructure will be critical to capitalize on shifting global alliances and sustain long-term growth.

India CRDMO Market 

Segmental Coverage

India CRDMO Market – By Service Type

Based on service type, India CRDMO Market is divided into Discovery Services, Preclinical & Clinical Development, and Manufacturing Services segments. The manufacturing services segment represents the largest service type in India CRDMO Market. The dominance is driven by the country’s strong foundation in small molecule production and cost-efficient infrastructure. Indian CRDMOs are increasingly preferred for commercial-scale manufacturing due to their compliance capabilities, scalability, and strategic role in global supply chain diversification. As demand for complex APIs and biologics rises, India’s manufacturing segment continues to expand, attracting global pharmaceutical and biotech firms seeking reliable, high-quality production partners across therapeutic modalities.

India CRDMO Market – By Therapeutic Area

Based on therapeutic area, India CRDMO Market is divided into Oncology, Infectious Diseases, and Cardiovascular & Metabolic Disorders segments. The oncology segment is the largest therapeutic segment in India CRDMO Market, due to rising global cancer incidence and demand for targeted therapies. Indian CRDMOs are increasingly involved in oncology drug discovery, clinical trials, and manufacturing of complex molecules, including cytotoxics and biologics. The segment benefits from strong research collaborations, regulatory support, and growing investments in precision medicine. As pharmaceutical companies prioritize oncology pipelines, India’s capabilities in scalable, cost-effective oncology solutions continue to position it as a preferred outsourcing destination.

India CRDMO Market – By End User

On the basis of end user, India CRDMO Market is divided into Pharmaceutical Companies, Biotechnology Firms, and Academic & Research Institutes segments. The pharmaceutical companies segment forms the largest end user in India CRDMO Market. The pharma companies’ market dominance is driven by their extensive outsourcing needs across drug discovery, development, and manufacturing. These firms seek cost-effective, scalable solutions to accelerate timelines and reduce R&D overheads. Indian CRDMOs offer integrated services, regulatory compliance, and global delivery capabilities, making them ideal partners for large pharma players. As innovation pipelines grow and demand for complex therapies rises, pharmaceutical companies continue to dominate CRDMO collaborations, fueling the expansion of India CRDMO Market.

India CRDMO Market – By Region

Geographically, India CRDMO Market is divided into East India, West India, South India, and North India. South India dominates India CRDMO Market due to its concentration of pharmaceutical hubs, proximity to regulatory bodies, and access to top-tier research institutions. Major pharma hubs across Telangana and Andhra Pradesh host major CRDMO players and benefit from strong infrastructure, skilled talent, and government support. This strategic positioning enhances collaboration, compliance, and scalability, making South India a preferred destination for global outsourcing. Its leadership in manufacturing and clinical development continues to drive market growth and innovation.

Competitive Landscape

Major companies operating in India CRDMO Market include Syngene International, Jubilant Biosys, Piramal Pharma Solutions, Dr. Reddy’s Laboratories, GVK Biosciences, Sai Life Sciences, Aragen Life Sciences, Anthem Biosciences, TCG Lifesciences, Laurus Labs, and Divi’s Laboratories. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

• In September 2025 – Symeres, a global CRDMO, acquired DGr Pharma, an  India-based firm, to enhance regulatory and consultancy services, integrating specialized capabilities in inhalation and peptide synthesis.

• In February 2025 - Syngene International, Aragen Life Sciences, Sai Life Sciences, Aurigene, Anthem Biosciences, Jubilant Biosys, Piramal Pharma Solutions, TCG Lifesciences, Neuland Laboratories, Laxai, and O2H Discovery together formed Innovative Pharmaceutical Services Organization (IPSO) as a trade body to advocate for policies, foster collaborations, and drive innovations in discovery, biomanufacturing, and specialized services.

Scope of the Report

Attributes	Details
Years Considered	Historical Data – 2019–2031
	Base Year – 2024
	Estimated Year – 2025
	Forecast Period – 2025–2031
Facts Covered	Revenue in USD Billion
Market Coverage	India
Product/ Service Segmentation	Service Type, Therapeutic Area, End User, Region
Key Players	Syngene International, Jubilant Biosys, Piramal Pharma Solutions, Dr. Reddy’s Laboratories, GVK Biosciences, Sai Life Sciences, Aragen Life Sciences, Anthem Biosciences, TCG Lifesciences, Laurus Labs, Divi’s Laboratories

 

 

By Service Type

• Discovery Services

• Preclinical & Clinical Development

• Manufacturing Services 

By Therapeutic Area

• Oncology

• Infectious Diseases

• Cardiovascular & Metabolic Disorders 

By End User

• Pharmaceutical Companies

• Biotechnology Firms

• Academic & Research Institutes

By Region

• East India

• West India

• South India

• North India

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Executive Summary
3. India CRDMO Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
         1. Rising Global Demand for Advanced Modalities
         2. Cost-Efficient Small Molecule Manufacturing
         3. Push to De-risk Global Supply Chains               
      2. Restraints
         1. Limited Funding and High Capital Costs
         2. Lagging ESG Compliance Standards   
      3. Opportunities
         1. Expansion into Biologics and RNA Therapeutics
         2. Strengthening R&D and Innovation Ecosystem       
      4. Challenges
         1. Talent Shortage and Need for 6–7x Workforce Expansion
         2. Regulatory Complexity and Approval Delays    
   3. Technological Advancements/Recent Developments
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
4. India CRDMO Market: Marketing Strategies
5. India CRDMO Market: Pricing Analysis
6. India CRDMO Market Overview
   1. Market Size & Forecast, 2019–2031
      1. By Value (USD Billion)
   2. Market Share & Forecast
      1. By Service Type
         1. Discovery Services
         2. Preclinical & Clinical Development
         3. Manufacturing Services  
      2. By Therapeutic Area
         1. Oncology
         2. Infectious Diseases
         3. Cardiovascular & Metabolic Disorders  
      3. By End User
         1. Pharmaceutical Companies
         2. Biotechnology Firms
         3. Academic & Research Institutes
      4. By Region
         1. East India
         2. West India
         3. South India
         4. North India
7. Competitive Landscape
   1. List of Key Players and Their Offerings
   2. India CRDMO Market Company Market Share Analysis, 2024
   3. Competitive Benchmarking, By Operating Parameters
   4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)
8. Impact of Escalating Geopolitical Tensions on India CRDMO Market
9. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
   1. Syngene International
   2. Jubilant Biosys
   3. Piramal Pharma Solutions
   4. Dr. Reddy’s Laboratories
   5. GVK Biosciences
   6. Sai Life Sciences
   7. Aragen Life Sciences
   8. Anthem Biosciences
   9. TCG Lifesciences
   10. Laurus Labs
   11. Divi’s Laboratories
   12. Other Prominent Players     
10. Key Strategic Recommendations
11. Research Methodology
    1. Qualitative Research
       1.  Primary & Secondary Research
    2.   Quantitative Research
    3.   Market Breakdown & Data Triangulation
       1.  Secondary Research
       2.  Primary Research
    4. Breakdown of Primary Research Respondents, By Region
    5.   Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable.

 

List of Figures

 

Figure 1       India CRDMO Segmentation

Figure 2       India CRDMO Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2024

Figure 4       India CRDMO Market Size, By Value (USD Billion), 2019–2031

Figure 5       India CRDMO Market Share, By Service Type, By Value, 2019–2031

Figure 6       India CRDMO Market Share, By Therapeutic Area, By Value, 2019–2031

Figure 7       India CRDMO Market Share, By End User, By Value, 2019–2031

Figure 6       India CRDMO Market Share, By Region, 2019–2031

 

List of Tables

 

Table 1         India CRDMO Market Size, By Value (USD Billion), 2019–2031

Table 2         India CRDMO Market Size, By Service Type, By Value, 2019–2031

Table 3         India CRDMO Market Size, By Therapeutic Area, By Value, 2019–2031

Table 4         India CRDMO Market Size, By End User, By Value, 2019–2031

Table 5         India CRDMO Market Size, By Region, By Value, 2019–2031

Table 6 Syngene International Company Overview

Table 7 Syngene International Financial Overview

Table 8 Jubilant Biosys Company Overview

Table 9 Jubilant Biosys Financial Overview

Table 10 Piramal Pharma Solutions Company Overview

Table 11 Piramal Pharma Solutions Financial Overview

Table 12 Dr. Reddy’s Laboratories Company Overview

Table 13 Dr. Reddy’s Laboratories Financial Overview

Table 14 GVK Biosciences Company Overview

Table 15 GVK Biosciences Financial Overview

Table 16 Sai Life Sciences Company Overview

Table 17 Sai Life Sciences Financial Overview

Table 18 Aragen Life Sciences Company Overview

Table 19 Aragen Life Sciences Financial Overview

Table 20 Anthem Biosciences Company Overview

Table 21 Anthem Biosciences Financial Overview

Table 22 TCG Lifesciences Company Overview

Table 23 TCG Lifesciences Financial Overview

Table 24 Laurus Labs Company Overview

Table 25 Laurus Labs Financial Overview

Table 26 Divi’s Laboratories Company Overview

Table 27 Divi’s Laboratories Financial Overview